Gastrointestinal hormones and bariatric surgery-induced weight loss

Obesity

Volumn 21, Issue 6, 2013, Pages 1093-1103

  Ionut, Viorica ^a   Burch, Miguel ^a   Youdim, Adrienne ^a   Bergman, Richard N ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; OXYNTOMODULIN; PEPTIDE YY;

BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; CALORIC RESTRICTION; DIET RESTRICTION; GASTRIC BANDING; GASTROPLASTY; HORMONE ACTION; HUMAN; LAPAROSCOPIC SURGERY; LIPID STORAGE; MAINTENANCE THERAPY; MALABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSTOPERATIVE PERIOD; REMISSION; REVIEW; SLEEVE GASTRECTOMY; STOMACH BYPASS; TREATMENT RESPONSE; VAGUS NERVE STIMULATION; VERTICAL BANDED GASTROPLASTY; WEIGHT CHANGE; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84881353226     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20364     Document Type: Review

References (80)

1. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK,. Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) Oct 2008; 16: 2323-2330.
2. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M,. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-273.
3. Heal DJ, Gosden J, Smith SL,. A review of late-stage CNS drug candidates for the treatment of obesity. Int J Obes (Lond) 2013; 37: 107-117.
4. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
5. Crookes PF,. Surgical treatment of morbid obesity. Annu Rev Med 2006; 57: 243-264.
6. Korner J, Inabnet W, Conwell IM, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006; 14: 1553-1561.
7. Buchwald H, Oien DM,. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009; 19: 1605-1611.
8. Nguyen NT, Masoomi H, Magno CP, Nguyen XM, Laugenour K, Lane J,. Trends in use of bariatric surgery, 2003-2008. J Am Coll Surg 2011; 213: 261-266.
9. Usinger L, Hansen KB, Kristiansen VB, Larsen S, Holst JJ, Knop FK,. Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding. Obes Surg 2011; 21: 625-632.
10. Garb J, Welch G, Zagarins S, Kuhn J, Romanelli J,. Bariatric surgery for the treatment of morbid obesity: a meta-analysis of weight loss outcomes for laparoscopic adjustable gastric banding and laparoscopic gastric bypass. Obes Surg 2009; 19: 1447-1455.
11. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248-256. e245.
12. Melissas J, Koukouraki S, Askoxylakis J, et al. Sleeve gastrectomy: a restrictive procedure? Obes Surg 2007; 17: 57-62.
13. Himpens J, Dobbeleir J, Peeters G,. Long-term results of laparoscopic sleeve gastrectomy for obesity. Ann Surg 2010; 252: 319-324.
14. Sandler BJ, Rumbaut R, Swain CP, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 2011; 25: 3028-3033.
15. Cohen R, Caravatto PP, Correa JL, et al. Glycemic control after stomach-sparing duodenal-jejunal bypass surgery in diabetic patients with low body mass index. Surg Obes Relat Dis 2012; 8: 375-380.
16. Kumar R, Lieske JC, Collazo-Clavell ML, et al. Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery 2011; 149: 654-661.
17. Odstrcil EA, Martinez JG, Santa Ana CA, et al. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr 2010; 92: 704-713.
18. Isbell JM, Tamboli RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care 2010; 33: 1438-1442.
19. Campos GM, Rabl C, Peeva S, et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg 2010; 14: 15-23.
20. Oliván B, Teixeira J, Bose M, et al. Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg 2009; 249: 948-953.
21. Rodríguez A, Becerril S, Valentí V, et al. Short-term effects of sleeve gastrectomy and caloric restriction on blood pressure in diet-induced obese rats. Obes Surg 2012; 22: 1481-1490.
22. Nauck MA,. Unraveling the science of incretin biology. Eur J Intern Med 2009; 20 (Suppl 2): S303-S308.
23. Burcelin R, Serino M, Cabou C,. A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism. Curr Opin Pharmacol 2009; 9: 744-752.
24. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780-785.
25. Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006; 55: 2025-2031.
26. Cummings DE, Overduin J, Foster-Schubert KE,. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89: 2608-2615.
27. Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 2009; 33: 786-795.
28. McLaughlin T, Peck M, Holst J, Deacon C,. Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab 2010; 95: 1851-1855.
29. Dirksen C, Hansen DL, Madsbad S, et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care 2010; 33: 375-377.
30. Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009; 250: 234-241.
31. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ,. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007; 3: 597-601.
32. Kampe J, Stefanidis A, Lockie SH, et al. Neural and humoral changes associated with the adjustable gastric band: insights from a rodent model. Int J Obes (Lond) 2012; 36: 1403-1411.
33. Alam ML, Van der Schueren BJ, Ahren B, et al. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 378-381.
34. Lugari R, Dei Cas A, Ugolotti D, et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 2004; 36: 111-115.
35. Valverde I, Puente J, Martín-Duce A, et al. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg 2005; 15: 387-397.
36. Falkén Y, Hellström PM, Holst JJ, Näslund E,. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 2011; 96: 2227-2235.
37. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ,. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006; 93: 210-215.
38. Pournaras DJ, Osborne A, Hawkins SC, et al. The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. Obes Surg 2010; 20: 56-60.
39. Ballantyne GH,. Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg 2006; 16: 651-658.
40. Valderas JP, Irribarra V, Boza C, et al. Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab 2010; 95: 1069-1075.
41. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK,. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008; 247: 401-407.
42. Bose M, Machineni S, Oliván B, et al. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring) 2010; 18: 1085-1091.
43. Morínigo R, Lacy AM, Casamitjana R, Delgado S, Gomis R, Vidal J,. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg 2006; 16: 1594-1601.
44. Morínigo R, Vidal J, Lacy AM, Delgado S, Casamitjana R, Gomis R,. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg 2008; 247: 270-275.
45. Chandarana K, Gelegen C, Karra E, et al. Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes 2011; 60: 810-818.
46. Zac-Varghese S, Tan T, Bloom SR,. Hormonal interactions between gut and brain. Discov Med 2010; 10: 543-552.
47. Laferrère B, Swerdlow N, Bawa B, et al. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 4072-4076.
48. De Silva A, Salem V, Long CJ, et al. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011; 14: 700-706.
49. Rao RS, Kini S,. GIP and bariatric surgery. Obes Surg 2011; 21: 244-252.
50. Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G,. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care 2009; 32: 375-380.
51. Mingrone G, Nolfe G, Gissey GC, et al. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion. Diabetologia 2009; 52: 873-881.
52. Castañeda TR, Tong J, Datta R, Culler M, Tschöp MH,. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol 2010; 31: 44-60.
53. Cummings DE, Shannon MH,. Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 2003; 88: 2999-3002.
54. Lee H, Te C, Koshy S, Teixeira JA, Pi-Sunyer FX, Laferrère B,. Does ghrelin really matter after bariatric surgery? Surg Obes Relat Dis 2006; 2: 538-548.
55. Frühbeck G, Diez-Caballero A, Gil MJ, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 2004; 14: 606-612.
56. Pérez-Romero N, Serra A, Granada ML, et al. Effects of two variants of Roux-en-Y Gastric bypass on metabolism behaviour: focus on plasma ghrelin concentrations over a 2-year follow-up. Obes Surg 2010; 20: 600-609.
57. Sundbom M, Holdstock C, Engström BE, Karlsson FA,. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg 2007; 17: 304-310.
58. Perathoner A, Weiss H, Santner W, et al. Vagal nerve dissection during pouch formation in laparoscopic Roux-Y-gastric bypass for technical simplification: does it matter? Obes Surg 2009; 19: 412-417.
59. Couce ME, Cottam D, Esplen J, Schauer P, Burguera B,. Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer. Obes Surg 2006; 16: 870-878.
60. Busetto L, Segato G, De Luca M, et al. High ghrelin concentration is not a predictor of less weight loss in morbidly obese women treated with laparoscopic adjustable gastric banding. Obes Surg 2006; 16: 1068-1074.
61. Dixon AF, Dixon JB, O'Brien PE,. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 2005; 90: 813-819.
62. Christou NV, Look D, McLean AP,. Pre- and post-prandial plasma ghrelin levels do not correlate with satiety or failure to achieve a successful outcome after Roux-en-Y gastric bypass. Obes Surg 2005; 15: 1017-1023.
63. Shin AC, Zheng H, Berthoud HR,. Vagal innervation of the hepatic portal vein and liver is not necessary for Roux-en-Y gastric bypass surgery-induced hypophagia, weight loss, and hypermetabolism. Ann Surg 2012; 255: 294-301.
64. Bueter M, Löwenstein C, Ashrafian H, et al. Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass. Obes Surg 2010; 20: 616-622.
65. Martin MB, Earle KR,. Laparoscopic adjustable gastric banding with truncal vagotomy: any increased weight loss? Surg Endosc 2011; 25: 2522-2525.
66. Angrisani L, Cutolo PP, Ciciriello MB, et al. Laparoscopic adjustable gastric banding with truncal vagotomy versus laparoscopic adjustable gastric banding alone: interim results of a prospective randomized trial. Surg Obes Relat Dis 2009; 5: 435-438.
67. Kral JG, Görtz L, Hermansson G, Wallin GS,. Gastroplasty for obesity: long-term weight loss improved by vagotomy. World J Surg 1993; 17: 75-78; discussion 79.
68. Houten SM, Watanabe M, Auwerx J,. Endocrine functions of bile acids. EMBO J 2006; 25: 1419-1425.
69. Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17: 1671-1677.
70. Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012; 153: 3613-3619.
71. Nakatani H, Kasama K, Oshiro T, Watanabe M, Hirose H, Itoh H,. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism 2009; 58: 1400-1407.
72. Katsuma S, Hirasawa A, Tsujimoto G,. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 386-390.
73. Camerini G, Adami G, Marinari GM, et al. Thirteen years of follow-up in patients with adjustable silicone gastric banding for obesity: weight loss and constant rate of late specific complications. Obes Surg 2004; 14: 1343-1348.
74. Freire RH, Borges MC, Alvarez-Leite JI, Toulson Davisson Correia MI,. Food quality, physical activity, and nutritional follow-up as determinant of weight regain after Roux-en-Y gastric bypass. Nutrition 2012; 28: 53-58.
75. Topart P, Becouarn G, Ritz P,. Weight loss is more sustained after biliopancreatic diversion with duodenal switch than Roux-en-Y gastric bypass in superobese patients. Surg Obes Relat Dis 2002, Mar 3. [Epub ahead of print]
76. Meguid MM, Glade MJ, Middleton FA,. Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition 2008; 24: 832-842.
77. Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg 2010; 20: 535-540.
78. Pories WJ, MacDonald KG, Morgan EJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr 1992; 55 (2 Suppl): 582S-585S.
79. Klein S, Fabbrini E, Patterson BW, et al. Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. Obesity (Silver Spring) 2012; 20: 1266-1272.
80. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006; 244: 741-749.